Anti-hyperuricemia composition
AssigneeMerck & Co., Inc.
InventorsJohn J. Baldwin, Frederick C. Novello
Life of this patent
Estimating the term…
Abstract
Compositions useful in the treatment of gout and hyperuricemia and containing a substituted 1,2,4-triazole as the active ingredient are provided, the triazoles being substituted at the 5 position with a pyridyl radical and at the 3 position with a phenyl or a pyridyl radical. Methods of preparing these substituted triazoles are described. Certain of the compounds are novel.
Claims8
A composition in unit dosage form for the treatment of hyperuricemia which comprises from about 25 mg. - 1.5 g. of a compound of the formula:
- ##SPC3##
- or a non-toxic pharmacologically acceptable salt thereof, intimately dispersed in a pharmaceutically acceptable carrier, wherein R.sub.1 is hydrogen, lower alkyl, lower alkanoyl, carbamoxy, di-lower alkylcarbamoyl or benzene sulfonyl;
- R.sub.3 is phenyl, lower alkylphenyl, tri-lower alkylphenyl, pryidyl, mono-lower alkylpyridyl or di-lower alkylpyridyl;
- and R.sub.5 is pyridyl, mono-lower alkylpyridyl or di-lower alkylpyridyl;
- including the mono N-oxides of those products wherein R.sub.3 and R.sub.5 are both pyridyl.
The method of treating hyperuricemia which comprises administering to a patient suffering from gout an effective amount of a compound of the formula:
- ##SPC4##
- or a non-toxic pharmacologically acceptable salt thereof, wherein R.sub.1 is hydrogen, lower alkyl, lower alkanoyl, carbamoyl, di-lower alkylcarbamoyl or benzenesulfonyl;
- R.sub.3 is phenyl, lower alkylphenyl, tri-lower alkylphenyl, pyridyl, mono-lower alkylpyridyl or di-lower akylpyridyl;
- and R.sub.5 is pyridyl, mono-lower alkylpyridyl or di-lower alkylpyridyl;
- including the mono N-oxides of those products wherein R.sub.3 and R.sub.5 are both pyridyl.
Dependencies are inferred from the claim text.